RCS - Allergy Therapeutics - EAACI Early Career Research Award

Allergy TherapeuticsAnnouncement

10/06/2025 07:05

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250610:nRSJ1667Ma&default-theme=true

RNS Number : 1667M  Allergy Therapeutics PLC  10 June 2025

 

 

Allergy Therapeutics plc

                                         ("Allergy Therapeutics", "ATL" or the "Group")

 

Allergy Therapeutics and EAACI announce winner of EAACI Early Career Research
Award

 

10 June 2025 Allergy Therapeutics (AIM: AGY), the fully integrated commercial
biotechnology company specialising in allergy immunotherapies, in
collaboration with the European Academy of Allergy and Clinical Immunology
(EAACI), today announces the winner of the EAACI Early Career Research Award.

 

The EAACI Early Career Research Award encourages young researchers and
clinicians to push the boundaries in allergen immunotherapy research that can
contribute to advancing allergy and immunology research and innovation, as
future leaders in the field. The recipient of this year's award is Dr. Janice
Layhadi, who is an early career researcher in the field of biomarker discovery
in allergen immunotherapy.

 

Manuel Llobet, Chief Executive Officer at Allergy Therapeutics, said: "We are
proud to support the EAACI Early Career Research Award and wish to
congratulate the winner, Dr. Janice Layhadi, a rising star whose research is
at the forefront of allergy and immunology research. Encouraging the next
generation of researchers is vital to advancing our understanding of allergy
and translating innovation into new therapeutic approaches that can
meaningfully improve the lives of people living with allergies. Together with
EAACI and through this award, we are committed to fostering scientific
excellence that we hope will shape the future of allergy research and,
ultimately, transform outcomes for patients."

 

María Jose Torres, President of the European Academy of Allergy and Clinical
Immunology, said: "I would like to congratulate Dr. Janice Layhadi and extend
my thanks to all the young researchers and clinicians for their applications
this year. Recognising and supporting early-career researchers is fundamental
to the advancement of the allergy research field and central to EAACI's
mission. This award reinforces our commitment to fostering innovation,
empowering the next generation of scientists and improving patient care."

 

Dr. Layhadi is a Research Associate at the Immunomodulation and Tolerance
Group (ITG) of Allergy & Clinical Immunology, at Imperial College London's
National Heart and Lung Institute. She completed her undergraduate studies in
Biochemistry at Imperial College London and pursued a Master's degree in
Pharmacology at Oxford University. Dr. Layhadi completed her PhD studies in
molecular sciences and pharmacology at the University of East Anglia in 2017
and joined Professor Mohamed Shamji's group at Imperial College London. Her
research interest primarily involves identifying underpinning molecular
mechanisms that are induced following allergen immunotherapy and correlate
with clinical efficacy.

 

Dr. Janice Layhadi said: "I am truly honoured to be the inaugural recipient of
the EAACI Early Career Research Award. This recognition is both humbling and
motivating, as it provides essential seed funding to generate the preliminary
data critical for securing independent research support. With this award, I
will continue to advance my investigations into the cellular and molecular
mechanisms influenced by allergen-specific immunotherapy, using a
comprehensive multi-omic approach. These opportunities are instrumental in
supporting my transition to research independence."

 

The EAACI Early Career Research Award provides an unrestricted research grant
of up to €30,000 and is open to EAACI Junior Members who have previously
published their high-impact research on allergy and immunology and
demonstrated their drive and dedication in the area of immunotherapy. The
planned research is expected to contribute to a better understanding of
allergic inflammation as well as improved diagnostic procedures and treatment,
enabling improved patient management and patient satisfaction.

 

The award will be presented to Dr. Layhadi by María Jose Torres, President of
EAACI, Mohamed Shamji, Secretary General of EAACI, Matthias Kramer,
International Medical Director at Allergy Therapeutics, and Anke Graessel,
Principal Medical Advisor Corporate at Allergy Therapeutics, at the opening
ceremony of the EAACI Annual Congress 2025, Glasgow, UK, on Friday, 13 June.
The congress will run until 16 June.

 

- ENDS -

 

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/ Seamus Fricker

Nigel Birks - Life Science Specialist Sales

Tamar Cranford Smith - Sales

+44 (0)20 7220 0500

 

ICR Healthcare

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@icrhealthcare.com
(mailto:allergytherapeutics@icrhealthcare.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapies that have the potential to
cure disease. The Group sells proprietary and third-party products from its
subsidiaries in nine major European countries and via distribution agreements
in an additional ten countries. For more information, please see
www.allergytherapeutics.com (http://www.allergytherapeutics.com) .

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASFDSMSEISESM